dr. abdulrahman mohammad al jassmi chief executive … cold chain... · dr. abdulrahman mohammad al...
TRANSCRIPT
Dr. Abdulrahman Mohammad Al Jassmi
Chief Executive Officer
Dubai Hospital
Dubai Health Authority
CHALLENGES AND
OPPORTUNITIES IN COLD CHAIN:
HEALTH CARE RELATED DRIVERS
• Integrating stakeholders to create value for the end users
• Maintaining the integrity of cold chain drugs throughout the
supply chain
• Emphasis on high performance execution
• Challenges.
AGENDA
Standard MMU.3: Medications are properly and safely
stored.
Standard GLD.7.1: Hospital leadership seeks and uses
data and information on the safety of the supply chain
for drugs, medical technology, and supplies to protect
patients and staff from contaminated, fake, and diverted
products.
JCI STANDARDS
•Physical changes:
•Appearance
•Melting point
•Clarity and color of solution
•Moisture
•Crystal modification (Polymorphism)
•Particle size •Chemical changes:
•Increase in Degradation
•Decrease of Assay •Microbial changes
WHAT ARE CHANGES?
•Regulatory Gap Analysis
•Personnel Training
•Review and Writing of SOPs (related to Cold Chain, Storage & Shipping) and
Documentation
•Temperature Mapping of Warehouse and Storage areas
•Qualification of Storage Equipment (Refrigerators/Freezers)
•Temperature Profile Studies in Transport (for uncontrolled transports)
•Test, Design and Qualification of Cold Chain Packaging Systems (outermost)
•Monitoring Solutions for Storage Conditions of Biosimilars/Drug products
•Maintenance of Cold Chain Management and Compliance.
COLD CHAIN COMPLIANCE
• Important for low- and middle-income countries
• Important for those vertically managed disease control
programs
• Each program owns the physical infrastructure for storing and
transporting health products within the health system.
• Some Programs are under increasing pressures to manage
larger volumes of higher-value products from the national to
service-delivery levels.
• > 50 countries had NO logistics systems that met the WHO
criteria of effective chain management.
• Many countries has chronic and enduring challenges of stock
management, vaccine distribution, and overall inefficiencies of
immunization supply chain and logistics systems.
WHY INTEGRATE SUPPLY CHAINS?
Medications may be stored within a storage area, in a pharmacy or pharmaceutical service, or on the patient care units in unit pharmacies or the
nursing station in the clinical unit.
a) Medications are stored under conditions suitable for product stability, including medications stored on individual patient care units.
b) Controlled substances are accurately accounted for according to applicable laws and regulations.
c) Medications and chemicals used to prepare medications are accurately labeled with contents, expiration dates, and warnings.
d) Concentrated electrolytes are not stored in care units unless clinically necessary, and when stored in care units there are safeguards in place to prevent inadvertent administration.
e) All medication storage areas, including medication storage areas on patient care units, are periodically inspected according to hospital policy to ensure that medications are stored properly.
f) Medications are protected from loss or theft throughout the hospital. (Also see FMS.4.1)
MMU.3
MEDICATIONS ARE PROPERLY AND SAFELY
STORED.
a) Hospital leadership identifies the supply chain of critical
supplies and medical technology.
b) Hospital leadership evaluates the integrity of each supplier in
that chain.
c) Hospital leadership makes resource decisions based on their
understanding of the risks in the supply chain.
d) Hospital leadership tracks critical supplies to prevent
diversion or substitution.
GLD.7.1
HOSPITAL LEADERSHIP SEEKS AND USES DATA AND
INFORMATION ON THE SAFETY OF THE SUPPLY
CHAIN FOR DRUGS, MEDICAL TECHNOLOGY, AND
SUPPLIES TO PROTECT PATIENTS AND STAFF FROM
CONTAMINATED, FAKE, AND DIVERTED PRODUCTS.
• Maintaining a secure “cold chain” for the benefit of the
patient.
• Maintaining a secure “cold chain” for the benefit of the
clinical trials.
• Industry and society benefit …
However:
• With excessive heat +/- freezing: Biotechnology Products are at
risk of loosing the therapeutic and financial value
VALUES
• 2020:The GCC’s market for European-made drugs and
medicines is expected to pass $10 billion. (reported by QNB
Capital)
• Annual drugs spending:
• Saudi Arabia: $2.8 billion
• UAE : $1.8 billion
• Kuwait: $374 million
GCC PHARMACEUTICAL MARKET
year Commercial
Biotechnology Industry
Global Market
1980s global biopharma market $200 billion
(13% of all biopharma
logistics spending)
2018 world sales of cold-chain
drugs and of biologics
such as vaccines and
blood plasma products
$300 billion
BIOPHARMA MARKET
* IMS Health
• A very substantial market for temperature-assured
transportation and packaging.
• Smaller quantities of products or test materials.
• a higher level of logistics services.
• Steady clinical-trial activity.
• Market size: under $3 billion in 2014.
CLINICAL TRIALS LOGISTICS
1. Strategy for a new market or climate zone to meet
new regulations, geographic distance and varying
validation processes.
2. How to mitigate risk with the lowest cost possible.
3. The rapid shift has led to confusion, waste and
inefficiency throughout the pharmaceutical supply
chain.
4. Risk on industry : exposure to theft, contamination,
counterfeiting and non-compliance.
CHALLENGES
5. The international pharmaceutical shipments often exchange
hands somewhere between 6 -15 times en route to a hospital,
clinic, pharmacy, doctor or patient.
6. Challenges on Manufacturers today
CHALLENGES
CONCLUSION
• Increased oversight, management, and control of environmental
conditions across the entire supply chain (from manufacturer to
consumer/patient)
• Global regulatory requirements have emphasized the importance
of assuring that product quality and integrity are not
compromised in the distribution channel.
• Responsibility for cold chain management ultimately resides with
the manufacturers
• Due to the presence of multiple uncontrolled variables in the
distribution process, developing an appropriate temperature and
humidity monitoring program is essential to protect the quality
of environmentally sensitive pharmaceutical product and ensure
patient safety.